No Data
CHINARES PHARMA (03320.HK): China Resources Double-Crane Pharmaceutical's net income in the first quarter was 0.507 billion yuan, a year-on-year decrease of 1.26%.
On April 28, Gelonghui reported that CHINARES PHARMA (03320.HK) announced that China Resources Double-Crane Pharmaceutical (600062.SH) achieved revenue of 3.079 billion yuan (RMB, the same below) in the first quarter of 2025, a year-on-year decrease of 2.10%. The net income attributable to the shareholders of China Resources Double-Crane Pharmaceutical was 0.507 billion yuan, a year-on-year decrease of 1.26%. The net income attributable to the shareholders of China Resources Double-Crane Pharmaceutical, excluding non-recurring gains and losses, was 0.486 billion yuan, a year-on-year increase of 22.16%.
Express News | China Resources Pharmaceutical - Qtrly Revenue RMB1.72 Bln for Dong-E-E-Jiao
CHINARES PHARMA: ANNOUNCEMENTUNAUDITED FINANCIAL RESULTS OF DONG-E-E-JIAOFOR THE THREE MONTHS ENDED 31 MARCH 2025
Express News | China Resources Pharmaceutical - Qtrly Net Profit of Jiangzhong Pharmaceutical RMB306.7 Mln
CHINARES PHARMA: ANNOUNCEMENTUNAUDITED FINANCIAL RESULTS OF JIANGZHONGPHARMACEUTICAL FOR THE THREE MONTHS ENDED31 MARCH 2025
CHINARES PHARMA: ANNOUNCEMENTUNAUDITED FINANCIAL RESULTS OF CR DOUBLE-CRANEFOR THE THREE MONTHS ENDED 31 MARCH 2025
